Point72 Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$39.6M Sell
602,374
-923,408
-61% -$71.9M 0.04% 556
2026
Q2
$114M Buy
+1,525,782
New +$107M 0.13% 172
2025
Q2
– Sell
-198,780
Closed -$6.87M – 2182
2025
Q1
$6.87M Buy
+198,780
New +$6.7M 0.02% 816
2023
Q4
– Sell
-5,265
Closed -$158K – 2170
2023
Q3
$139K Sell
5,265
-61,409
-92% -$1.74M ﹤0.01% 1875
2023
Q2
$1.15M Sell
66,674
-32,500
-33% -$489K ﹤0.01% 1122
2023
Q1
$1.64M Buy
+99,174
New +$1.16M 0.01% 1016
2022
Q1
– Sell
-50,312
Closed -$839K – 1172
2021
Q4
$839K Buy
+50,312
New +$2.13M ﹤0.01% 936
2019
Q3
– Sell
-13,200
Closed -$356K – 1142
2019
Q2
$356K Buy
+13,200
New +$360K ﹤0.01% 897

Other funds holding BBIO

Point72 Asset Management's BBIO Position: Q3 2026 in Review

Point72 Asset Management reduced its BridgeBio Pharma (BBIO) stake by 61% in Q3 2026, selling an estimated $71.9M and leaving 602,374 shares worth $39.6M. The position accounts for 0.04% of the portfolio, ranked #556.

Point72 Asset Management first reported a position in BBIO in Q2 2019 and has held it in 8 quarters since. The position peaked at $114M in Q2 2026. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Point72 Asset Management held 602,374 shares of BridgeBio Pharma worth $39.6M as of Q3 2026.
  • Point72 Asset Management sold 923,408 BridgeBio Pharma shares in Q3 2026, an estimated $71.9M.
  • BridgeBio Pharma made up 0.04% of Point72 Asset Management's portfolio in Q3 2026, its #556 holding.
  • Point72 Asset Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 8 quarters since.
  • Point72 Asset Management's BridgeBio Pharma position peaked at $114M in Q2 2026.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.